Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer

Real-World Evidence: Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) is organized by CME Outfitters, LLC.

Premiere Date: Monday, April 27, 2020
Credit Expiration Date: Tuesday, April 27, 2021

This activity offers CE credit for:
• Physicians (CME)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Statement of Need:
While clinical trials are designed to demonstrate efficacy and safety under controlled conditions, the highly selected trial populations in these studies often do not accurately reflect the general cancer patient population. The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes represents a broader spectrum of patients and can help provide guidance on how to apply randomized, controlled trial (RCT) results more broadly.

The potential for RWE is particularly significant in oncology settings, as the optimal use of agents cannot be fully characterized prior to routine clinical use. RWE, when effectively deployed, can help bridge the gap by aiding in increasing external validity and generating evidence on the factors that determine treatment effects in the real world.

This CME Outfitters Snack will feature expert faculty discussing RCTs, RWD, and RWE, with a focus on the current RWE in the field of cyclin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer (MBC).

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Analyze real-world evidence in terms of study validity, study design, and data source to accurately interpret findings in an oncology setting.
• Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.